Irvine, California headquartered Aerie Pharmaceuticals Inc.'s stock finished Thursday's session 0.26% lower at $37.70 with a total trading volume of 198,760 shares. The Company's shares have advanced 54.83% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 0.39% and 54.32%, respectively. Furthermore, shares of Aerie Pharma, which focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases, have a Relative Strength Index (RSI) of 49.26.
On December 23rd, 2016, Aerie Pharma announced that it has been notified by its third party manufacturing vendor that the manufacturing line related to Rhopressa[TM] in their Tampa, Florida facility will not be ready for pre-approval inspection by the FDA until the end of February 2017. In October 2016, the Rhopressa[TM] New Drug Application was withdrawn due to the contract drug product manufacturer not being prepared for pre-approval inspection by the FDA. The contract drug product manufacturer had previously advised Aerie and the FDA that it expected to be prepared for FDA inspection in January 2017. The free research report on AERI is available at:
Shares in Hayward, California headquartered Impax Laboratories Inc. ended at $12.85, up 0.78% from the last trading session. The stock recorded a trading volume of 864,101 shares. The Company's shares are trading 19.29% below their 50-day moving average. Moreover, shares of Impax Laboratories, which develops, manufactures, and markets bioequivalent pharmaceutical products, have an RSI of 37.01.
On December 20th, 2016, Impax Laboratories announced that J. Kevin Buchi, a member of Impax's Board of Directors, has been appointed Interim President and CEO. The Company's Board has come to a mutual agreement with G. Frederick Wilkinson that the latter separate from his positions as President and CEO and as a member of the Board, effective immediately.
On December 28th, 2016, research firm Janney initiated a 'Neutral' rating on the Company's stock, with a target price of $15 per share.
The complimentary report on IPXL can be downloaded at:
San Diego, California headquartered Retrophin Inc.'s stock ended yesterday's session 0.63% higher at $19.20 with a total trading volume of 362,629 shares. The Company's shares are trading 5.16% above their 200-day moving average. Shares of the Company, which focuses on the development, acquisition, and commercialization of therapies for the treatment of serious, catastrophic, or rare diseases, have an RSI of 44.70.
On November 19th, 2016, Retrophin announced additional results from the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder without an FDA-approved pharmacologic treatment that often leads to end-stage renal disease. An analysis of the secondary endpoint presented showed that a significantly greater proportion of patients receiving sparsentan achieved modified partial remission of proteinuria, compared to irbesartan-treated patients. Modified partial remission, defined as proteinuria levels of less than or equal to 1.5 g/g and greater than 40% reduction of proteinuria from baseline, is associated with long-term preservation of renal function in FSGS. Visit us today and download our complete research report on RTRX for free at:
At the close on Thursday, shares in Cambridge, the UK-based GW Pharmaceuticals PLC recorded a trading volume of 218,003 shares. The stock finished 0.24% lower at $111.43. The Company's shares have surged 60.47% since the start of this year. The stock is trading above its 200-day moving average by 13.10%. Furthermore, shares of GW Pharma, which engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant, have an RSI of 42.41.
On December 5th, 2016, GW Pharma announced additional positive Epidiolex® Phase 3 data at the 70th Annual Meeting of the American Epilepsy Society. These data are from the positive pivotal Phase 3 study of Epidiolex in Dravet syndrome and the first pivotal Phase 3 study of Epidiolex in Lennox-Gastaut syndrome, both reported earlier this year. The Company stated that each pivotal Phase 3 study achieved the primary endpoint demonstrating a statistically significant difference between Epidiolex and placebo in seizure frequency reduction during the 14-week treatment period.
On December 5th, 2016, research firm Cantor Fitzgerald reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $182 a share to $208 a share. Get free access to your technical report on GWPH at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA